ClinicalTrials.gg
Enrolling by invitationNCT07056946Updated Nov 20, 2026

Supra Inguinal Fascia Iliaca Block Versus Ultrasound-guided Caudal Analgesia for Pediatrics Undergoing Anterior and Lateral Thigh Surgeries: A Randomized Controlled Trial

An interventional study of Fascia Iliaca Nerve Block and Caudal Block Anesthesia in Cancer Bone, sponsored by National Cancer Institute, Egypt. Enrolling by invitation at 2 sites in Egypt. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by National Cancer Institute, Egypt · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now Enrolling by invitationStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
5 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Bone Neoplasms with a site in Egypt — 2 open to participants now, 2 under way, none of them phase 3. Bone Neoplasms · Egypt.

Started
2025
the only one that year
No phase
4 of 12
1 open now
Registered
12th of 12
by date
Lead sponsor
2 of 12
National Cancer Institute, Egypt

Among the 12 studies in Bone Neoplasms with a site in Egypt, this one is the only one that started in 2025, is one of 4 with no phase, and was the 12th registered.

Bone Neoplasms

259 studies on the registry are indexed under Bone Neoplasms; 70 are open to participants now.

Browse Bone Neoplasms studies →

Open to participants now

2 of the 12 studies in Bone Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 54 Bone Neoplasms studies recruiting now, 35 (65%) set no upper age limit and 13 (24%) stop at 75 or younger; 25 take children under 18; 4 take healthy volunteers.

This study: 5 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Bone Neoplasms with a site in Egypt, or all of them as a file.
02

Study summary

patients will then be randomized in the two groups.

  1. Group C: in this group children will receive US-guided caudal analgesia (CA) . The caudal block will be performed
  2. Group S: in this group children will receive lower limb peripheral nerve blocks in the form of US-guided fascia iliaca Block.
Read the detailed description

After assessment of eligibility criteria, a clinical nurse independent of the protocol will obtain the randomization number and patients will then be randomized in the two groups. Treatment allocation will follow the order of a predetermined randomization list and will be generated using random blocks. Randomized will be done through computer program with patient blinded to the type of intervention (single blinded).

  1. Group C: in this group children will receive US-guided caudal analgesia (CA) after GA. The caudal block will be performed by visualizing the sacral hiatus at the level of the sacral cornu after placing the probe transversely obtaining a short axis view, two hyperechoic lines will appear between the sacral cornu the superficial line is the sacrococcygeal ligament which will be pierced by the needle 22-gauge echogenic non-stimulating 5-cm needle (Ultraplex; B. Braun Medical Bethlehem PA, USA) using the out-of-plane approach. After confirming the absence of any blood or cerebrospinal fluid in the aspiration the caudal mixture (1 mL/kg of 0.125% bupivacaine a maximum volume of 20 mL will be used) will be injected.
  2. Group S: in this group children will receive lower limb peripheral nerve blocks in the form of US-guided fascia iliaca Block.

American Society of Anesthiologists recommends monitors, intravenous line, and O2 (3 L/min) through the nasal cannula will be used. All blocks will be executed under the guidance of a 5-13 MHz linear ultrasound probe covered in a sterile sheath and attached to a Sonosite (M- Turbo; SonoSite Inc. Bothell WA USA) portable ultrasound machine. Preoperatively the maximum dose of bupivacaine will be calculated (2 mg/kg) so as not to exceed the dose during injection in either group.

03

Conditions studied

  • Cancer Bone

Browse trials for

Keywords

  • Supra inguinal fascia iliaca Block ,Caudal Analgesia,Pediatrics
04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 5-12 years
  • scheduled for anterior and lateral thigh Surgeries
  • (ASA) physical status II or III

Exclusion criteria

Exclusion Criteria:

  • Refusal of parental consent
  • Allergy to any local anesthetics
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Group C: in this group children will receive US-guided caudal analgesia (CA) after GA.

    The caudal block will be performed by visualizing the sacral hiatus at the level of the sacral cornu after placing the probe transversely obtaining a short axis view

    Other: Caudal Block Anesthesia

  • Experimental
    Group S: in this group children will receive lower limb peripheral nerve blocks in the form of US

    With the patient in the proper position, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. After a skin wheal is made, the needle is inserted in-plane

    Other: Fascia Iliaca Nerve Block

Interventions

  • OtherFascia Iliaca Nerve Block

    With the patient in the proper position, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. After a skin wheal is made, the needle is inserted in-plane

  • OtherCaudal Block Anesthesia

    The caudal block will be performed by visualizing the sacral hiatus at the level of the sacral cornu after placing the probe transversely obtaining a short axis view, two hyperechoic lines will appear between the sacral cornu the superficial line is the sacrococcygeal ligament

06

What researchers measure

Primary outcomes

  1. • Estimation of time of first rescue postoperative analgesia

    Time frame: 4 hours postoperatively

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 36 non-industry interventional studies with no phase under Bone Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's planned 17 months is below that.

Counting every sponsor, half of 42 studies reached it within 50 months; a quarter within 14 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Aug 2025 → Jul 2025, primary completion Aug 2026 → Dec 2026 and completion Aug 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2025
First posted
Jul 9, 2025
StartActual
Jul 1, 2025was Aug 2025
Primary completionEst.
Dec 30, 2026was Aug 2026
CompletionEst.
Dec 30, 2026was Aug 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Enrolling by invitation
changed Nov 20, 2026
Start date
Aug 1, 2025→Jul 1, 2025
Nov 20, 2026
Primary completion
Aug 1, 2026→Dec 30, 2026
Nov 20, 2026
Study completion
Aug 1, 2026→Dec 30, 2026
Nov 20, 2026
Eligibility
Minimum age 1 Year→5 Years; Maximum age 7 Years→12 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAge 15-712 years
Nov 20, 2026
Interventions
Arm changed Group B: in this group children will receive lower limb peripheral nerve blocks in the form of US→Group S: in this group children will receive lower limb peripheral nerve blocks in the form of US
Nov 20, 2026
Show all 2 updates
  1. Nov 20, 2026
    Completed→Enrolling by invitation
    Start date Aug 1, 2025→Jul 1, 2025
    Primary completion Aug 1, 2026→Dec 30, 2026
    Study completion Aug 1, 2026→Dec 30, 2026
    Eligibility Minimum age 1 Year→5 Years; Maximum age 7 Years→12 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAge 15-712 years
    Interventions Arm changed Group B: in this group children will receive lower limb peripheral nerve blocks in the form of US→Group S: in this group children will receive lower limb peripheral nerve blocks in the form of US
    + 2 other changes: verification date and description
  2. Nov 18, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07056946
Responsible party
Suzan Adlan Abdelrahman (assistant professor, National Cancer Institute, Egypt) — Principal investigator
First posted
Jul 9, 2025
Start date
Jul 1, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Nov 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion